168 related articles for article (PubMed ID: 26300505)
1. Cellular and molecular aspects of diabetic nephropathy; the role of VEGF-A.
Carranza K; Veron D; Cercado A; Bautista N; Pozo W; Tufro A; Veron D
Nefrologia; 2015; 35(2):131-8. PubMed ID: 26300505
[TBL] [Abstract][Full Text] [Related]
2. VEGF and angiopoietins in diabetic glomerulopathy: how far for a new treatment?
Dei Cas A; Gnudi L
Metabolism; 2012 Dec; 61(12):1666-73. PubMed ID: 22554833
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy.
Ziyadeh FN; Wolf G
Curr Diabetes Rev; 2008 Feb; 4(1):39-45. PubMed ID: 18220694
[TBL] [Abstract][Full Text] [Related]
4. Imbalance of glomerular VEGF-NO axis in diabetic rats: prevention by chronic therapy with propyl gallate.
Tian S; Gan Y; Li J; Wang L; Shen J; Liu T; Ye T; Liu H; Liu D; Deng Y; Wang W
J Nephrol; 2011; 24(4):499-506. PubMed ID: 21425119
[TBL] [Abstract][Full Text] [Related]
5. The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy.
Sato W; Kosugi T; Zhang L; Roncal CA; Heinig M; Campbell-Thompson M; Yuzawa Y; Atkinson MA; Grant MB; Croker BP; Nakagawa T
Lab Invest; 2008 Sep; 88(9):949-61. PubMed ID: 18607348
[TBL] [Abstract][Full Text] [Related]
6. Podocyte-specific VEGF-a gain of function induces nodular glomerulosclerosis in eNOS null mice.
Veron D; Aggarwal PK; Velazquez H; Kashgarian M; Moeckel G; Tufro A
J Am Soc Nephrol; 2014 Aug; 25(8):1814-24. PubMed ID: 24578128
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor and diabetic nephropathy.
Chen S; Ziyadeh FN
Curr Diab Rep; 2008 Dec; 8(6):470-6. PubMed ID: 18990304
[TBL] [Abstract][Full Text] [Related]
8. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy.
Nakagawa T; Sato W; Glushakova O; Heinig M; Clarke T; Campbell-Thompson M; Yuzawa Y; Atkinson MA; Johnson RJ; Croker B
J Am Soc Nephrol; 2007 Feb; 18(2):539-50. PubMed ID: 17202420
[TBL] [Abstract][Full Text] [Related]
9. Do adenosine receptors offer new therapeutic options for diabetic nephropathy?
San MartÃn R; Valladares D; Roa H; Troncoso E; Sobrevia L
Curr Vasc Pharmacol; 2009 Oct; 7(4):450-9. PubMed ID: 19485887
[TBL] [Abstract][Full Text] [Related]
10. Propyl gallate plays a nephroprotective role in early stage of diabetic nephropathy associated with suppression of glomerular endothelial cell proliferation and angiogenesis.
Tian S; Tang J; Liu H; Wang L; Shen J; Li J; Gan Y
Exp Diabetes Res; 2012; 2012():209567. PubMed ID: 22988451
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: Biological effects and advanced glycosilation end products modulation.
Pala L; Cresci B; Manuelli C; Maggi E; Yamaguchi YF; Cappugi P; Rotella CM; Giannini S
Microvasc Res; 2005 Nov; 70(3):179-88. PubMed ID: 16271941
[TBL] [Abstract][Full Text] [Related]
12. Endothelial cell-specific overexpression of endothelial nitric oxide synthase in Ins2Akita mice exacerbates diabetic nephropathy.
Natarajan M; Habib SL; Reddick RL; Delma CR; Manickam K; Prihoda TJ; Werner SL; Mohan S
J Diabetes Complications; 2019 Jan; 33(1):23-32. PubMed ID: 30424931
[TBL] [Abstract][Full Text] [Related]
13. Angiogenic factors.
Khoury CC; Ziyadeh FN
Contrib Nephrol; 2011; 170():83-92. PubMed ID: 21659761
[TBL] [Abstract][Full Text] [Related]
14. Angiopoietins and diabetic nephropathy.
Gnudi L
Diabetologia; 2016 Aug; 59(8):1616-20. PubMed ID: 27207083
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy.
Baelde HJ; Eikmans M; Doran PP; Lappin DW; de Heer E; Bruijn JA
Am J Kidney Dis; 2004 Apr; 43(4):636-50. PubMed ID: 15042541
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes.
Schrijvers BF; De Vriese AS; Tilton RG; Van de Voorde J; Denner L; Lameire NH; Flyvbjerg A
Horm Metab Res; 2005 Jan; 37(1):21-5. PubMed ID: 15702434
[TBL] [Abstract][Full Text] [Related]
17. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man.
Hohenstein B; Hausknecht B; Boehmer K; Riess R; Brekken RA; Hugo CP
Kidney Int; 2006 May; 69(9):1654-61. PubMed ID: 16541023
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of calmodulin in pancreatic beta cells induces diabetic nephropathy.
Yuzawa Y; Niki I; Kosugi T; Maruyama S; Yoshida F; Takeda M; Tagawa Y; Kaneko Y; Kimura T; Kato N; Yamamoto J; Sato W; Nakagawa T; Matsuo S
J Am Soc Nephrol; 2008 Sep; 19(9):1701-11. PubMed ID: 18525005
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic nephropathy of type 1 diabetes mellitus.
Mironidou-Tzouveleki M; Tsartsalis S; Tomos C
Curr Drug Targets; 2011 Jan; 12(1):107-14. PubMed ID: 20735351
[TBL] [Abstract][Full Text] [Related]
20. [The effects of VEGF-R inhibitor on podocytopathy of rats with type I diabetic nephropathy].
Wang S; Li Y; Huang YJ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Sep; 27(9):1003-6. PubMed ID: 21906476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
